A method of training a machine learning algorithm, the method implemented by a computer comprising a processor and a memory, the method comprising: obtaining a training dataset, wherein the training dataset comprises a set of sample data, including first sample data, for a corresponding set of samples including a first sample, wherein the first sample data comprises a plurality of single cell and/or particle events and respective parameters; and training the machine learning algorithm comprising incremental learning using the set of sample data.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
2.
COMPOSITIONS COMPRISING AN INHIBITOR OF GALECTIN-3
The present disclosure provides a composition comprising a compound of Formula I, or pharmaceutically acceptable salt thereof, and/or a compound of Formula II, or pharmaceutically acceptable salt thereof, for use in inhibiting Galectin-3. The composition may be for use in the treatment and/or prevention of a disease, disorder, state or condition wherein inhibiting Galectin-3 would be beneficial for the treatment and/or prevention of the disease, disorder, state or condition. The disease, disorder, state or condition may be cancer, cancer metastasis, fibrosis, inflammation, diabetes and/or one or more other disease, disorder, state or condition affected and/or mediated by Galectin-3.
The present disclosure provides a composition comprising a compound of Formula X, or a pharmaceutically acceptable salt thereof, and/or a compound of Formula Y, or a pharmaceutically acceptable salt thereof, and/or a compound of Formula Z, or a pharmaceutically acceptable salt thereof, for use in inhibiting Galectin-3. The composition may be for use in the treatment and/or prevention of a disease, disorder, state or condition wherein inhibiting Galectin-3 would be beneficial for the treatment and/or prevention of the disease, disorder, state or condition. The disease, disorder, state or condition may be cancer, cancer metastasis, fibrosis, inflammation, diabetes and/or one or more other disease, disorder, state or condition affected and/or mediated by Galectin-3.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/472 - Isoquinoléines non condensées, p.ex. papavérine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
The invention provides a compound of formula (I), or a pharmaceutically-acceptable salt, solvate or clathrate thereof, for use in killing, inhibiting, or preventing the growth of a microbial biofilm, formula (I) wherein R1, AA1, AA2, AA3, AA4, AA5, AA6, AA7, R8, R9, R10, R11 and Z have meanings given in the description. Preferably, the biofilms are produced by Staphylococcus aureus or Staphylococcus epidermidis.
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
An apparatus for forming CO2-free hydrogen and carbon nanomaterials from methane is described. The apparatus comprises: a gliding arc discharge, GAD, device arranged to generate a plasma; and a passageway including an inlet for the methane and an outlet for the hydrogen and carbon and/or carbon nanomaterials, wherein the passageway extends, at least in part, through the GAD device wherein, in use, the methane is reacted in the generated plasma at temperatures of at most 400° C. and atmospheric pressure, thereby forming the hydrogen from at least some of the methane. A method is also described.
C01B 3/24 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés organiques gazeux ou liquides d'hydrocarbures
The present invention relates to solid compositions comprising microparticles of glecaprevir and/or pibrentasvir dispersed within a matrix comprising a first excipient and a second excipient. The present invention also relates to microneedle arrays, implantable rods, aqueous dispersions, and pharmaceutical compositions derived from said solid compositions and uses for the same.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinoxaline, phénazine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A process comprises reacting a carbonyl compound with an alkene compound in the presence of an iridium catalyst, wherein the carbonyl compound comprises a nitrogen-based group in a position that is α or β to the carbonyl group and wherein the process comprises the step of α- alkylation of the carbonyl compound by carbon-carbon bond formation between the carbon atom α to the carbonyl group and a carbon atom of the double bond of the alkene compound. The process allows the preparation of amino acid derivatives and other compounds. The process has the flexibility to yield compounds with a range of substituents, with good levels of step and atom economy and selectivity.
C07C 221/00 - Préparation de composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné
C07C 231/12 - Préparation d'amides d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes carboxamide
C07D 209/26 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile avec un radical acyle lié à l'atome d'azote du cycle
A three-dimensional metal-organic framework, MOF, comprising a plurality of crystallographically-ordered heterolinkers, including a first linker and a second linker, respectively periodically arranged between metal nodes, defining cages having a plurality of mutually different window types, including a first window type and a second window type, therebetween, wherein the respective window types correspondingly comprise mutually different heterolinker arrangements.
The present invention relates to a method of determining or identifying whether a mesenchymal stem cell has high proliferative capacity, a method of selecting said mesenchymal stem cells, a mesenchymal stem cell having high proliferative capacity, a pharmaceutical composition thereof, its method of preparation, and its use as a medicament.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour le typage de tissu ou de cellule, p.ex. sondes d’antigène leucocytaire humain [HLA]
The invention provides novel antibacterial compounds of formulae IA, IB and IC as defined herein.
The invention provides novel antibacterial compounds of formulae IA, IB and IC as defined herein.
The invention provides novel antibacterial compounds of formulae IA, IB and IC as defined herein.
Optionally, the antibacterial compounds can be bonded to a delivery agent that is capable of bonding to one or more structures on a bacterial cell membrane. The invention also provides the use of such compounds in treating or preventing bacterial infections, and processes for their synthesis.
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
A61K 38/00 - Préparations médicinales contenant des peptides
The present invention relates to methods of producing implantable rods and microneedle arrays comprising nanoparticles of atovaquone, as well as such implantable rods and microneedle arrays themselves and therapeutic uses thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p.ex. quinones, vitamine K1, anthraline
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
G06V 10/40 - Extraction de caractéristiques d’images ou de vidéos
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
An apparatus (1) including: a differential mobility separation, DMS, device (11) comprising: a set of mutually spaced apart electrodes (111), including a first electrode (111A) and a second electrode (111B) having a region R therebetween; a DC power supply (112) (not shown) configured to apply respective DC potentials to the set of electrodes (111) to provide an electric field E in the region R; a gas G source arranged to provide a flow F of gas G in the region R transverse, preferably orthogonal, to the electric field E; and an ion inlet (113) disposed to introduce ions I into the region R, wherein the ions I are mutually spatially separated in the flow F of the gas G according to their respective differential gas phase ion mobilities by the electric field E and wherein the mutually spatially separated ions S are correspondingly deposited on the first electrode (111A) as respective mutually spatially separated analytes A; and wherein the DMS device (11) comprises an interface (114) to an analyser (115) for analysis of the mutually spatially separated analytes A deposited on the first electrode (111A).
The present invention relates to solid compositions comprising nanoparticles of a Rifamycin, such a Rifapentine, dispersed within a matrix comprising a first excipient and a second excipient. The present invention also relates to microneedle arrays, implantable rods, aqueous dispersions, and pharmaceutical compositions derived from said solid compositions and uses for the same.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
16.
ANTI-MEDIN IMMUNOTHERAPY FOR VASCULAR AGING AND RELATED DEMENTIAS
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF LIVERPOOL (Royaume‑Uni)
Inventeur(s)
Migrino, Raymond
Li, Ming
Madine, Jillian
Abrégé
In one aspect, the invention relates to synthetic medin peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for disrupting medin toxicity; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating, reducing or preventing vascular dy sfunction, cognitive dysfunction, neurodegeneration, neurovascular pathyology, coronary artery disease and/or ischemic heart disease using the disclosed synthetic medin peptides and compositions thereof.
An electrochemical cell for the reduction of carbon dioxide to carbon monoxide. The electrochemical cell comprises a cathode, an anode, an ion-exchange membrane separating the anode and cathode, and a gas supply for providing carbon dioxide gas to the cathode; wherein the cathode is provided by a gas diffusion electrode comprising a gas diffusion layer and a molecular catalyst. The ion-exchange membrane comprises a cation-exchange layer and the ion-exchange membrane is arranged in direct contact with the cathode and the anode. The molecular catalyst comprises cobalt and an organic ligand. A method of electrochemical reduction of carbon dioxide in an electrochemical cell is also disclosed.
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stables; Assemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
C25B 11/032 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par la configuration ou la forme perforées ou foraminées Électrodes poreuses Électrodes à diffusion de gaz
A method of characterizing a liquid exposed to ionizing radiation is provided. The method includes including an oxidizing agent and/or a reducing agent of a redox pair in the liquid, thereby providing a corresponding redox couple; and determining a first redox potential due, at least in part, to the redox couple while exposing the liquid to the ionizing radiation.
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
G01N 27/48 - Systèmes utilisant la polarographie, c. à d. la mesure des variations d'intensité sous une tension qui varie lentement
19.
APPARATUS FOR CONTROLLING A COMPOSITION OF A PLASMA
Disclosed is an apparatus for controlling a composition of a plasma, comprising a pair of electrodes having a dielectric barrier therebetween, the apparatus further comprising: a temperature control unit in thermal contact with one of the electrodes or the dielectric barrier; a sensor configured to measure a temperature of one of electrodes or the dielectric barrier; a detector configured to determine a concentration of a primary chemical species of the plasma; and a processor configured to control the temperature control unit based on the measured temperature and the determined concentration.
ab7-yy1-xx422, or a mixture thereof; and x is from 0 to 1. The solid crystalline material suitably provides a solid ionic conductor for use in a solid-state battery. A solid crystalline material comprising a solid solution, a solid-state battery comprising the solid crystalline material and a method of preparing the solid crystalline are also disclosed.
The Research Foundation for The State University of New York (USA)
The University of Liverpool (Royaume‑Uni)
Inventeur(s)
Pisconti, Addolorata
Jones, Fiona Kate
Johnson, Kirsty Anne
Abrégé
The present disclosure is directed to methods of treatment, including treatment of a myopathy by administering to a subject in need thereof an elastase inhibitor in combination with a glucocorticoid. The present disclosure is also directed to pharmaceutical compositions that include an elastase inhibitor that can be used in such treatment.
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone substitués en position 21, p.ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
22.
APPARATUS AND METHOD COMBINING PAPER CHROMATOGRAPHY AND PAPER SPRAY MASS SPECTROMETRY
A method comprising: providing a sample comprising analytes, for example in a matrix, on a substrate, for example a monolithic substrate, comprising a stationary phase; separating the analytes, for example mutually and/or relative to the matrix, on the substrate using a mobile phase; and analysing the separated analytes using mass spectrometry, wherein the substrate provides, at least in part, an ion source for ionising the separated analytes.
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p.ex. fermetures étanches au vide; Dispositions pour le réglage externe des composants électronoptiques ou ionoptiques
H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
G01N 30/90 - Chromatographie sur plaque, p.ex. chromatographie en couche mince ou chromatographie sur papier
A method of forming an implant having a porous tissue ingrowth structure and a bearing support structure. The method includes depositing a first layer of a metal powder onto a substrate, scanning a laser beam over the powder so as to sinter the metal powder at predetermined locations, depositing at least one layer of the metal powder onto the first layer and repeating the scanning of the laser beam.
B22F 3/11 - Fabrication de pièces ou d'objets poreux
B22F 5/10 - Fabrication de pièces ou d'objets à partir de poudres métalliques caractérisée par la forme particulière du produit à réaliser d'articles avec des cavités ou des trous, non prévue dans les sous-groupes précédents
B22F 10/28 - Fusion sur lit de poudre, p.ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p.ex. le lissage de la surface, la densité, la porosité ou des structures creuses
B23K 26/382 - Enlèvement de matière par perçage ou découpage par perçage
B29C 37/00 - FAÇONNAGE OU ASSEMBLAGE DES MATIÈRES PLASTIQUES; FAÇONNAGE DES MATIÈRES À L'ÉTAT PLASTIQUE NON PRÉVU AILLEURS; POST-TRAITEMENT DES PRODUITS FAÇONNÉS, p.ex. RÉPARATION - Eléments constitutifs, détails, accessoires ou opérations auxiliaires non couverts par le groupe ou
B29C 45/14 - Moulage par injection, c. à d. en forçant un volume déterminé de matière à mouler par une buse d'injection dans un moule fermé; Appareils à cet effet en incorporant des parties ou des couches préformées, p.ex. moulage par injection autour d'inserts ou sur des objets à recouvrir
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B33Y 80/00 - Produits obtenus par fabrication additive
C23C 4/02 - Pré-traitement du matériau à revêtir, p.ex. pour revêtement de parties déterminées de la surface
C23C 24/10 - Revêtement à partir de poudres inorganiques en utilisant la chaleur ou une pression et la chaleur avec formation d'une phase liquide intermédiaire dans la couche
C23C 26/02 - Revêtements non prévus par les groupes par application au substrat de matériaux fondus
The invention provides novel antibacterial compounds of formula I as defined herein. (I) The invention also provides the use of such compounds in treating or preventing bacterial infections, and processes for their synthesis.
C07K 11/02 - Depsipeptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés cycliques, p.ex. valinomycines
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
An electrochemical cell comprising a gas diffusion electrode for the electrochemical reduction of carbon dioxide. The gas diffusion electrode comprises a gas diffusion layer and a nickel or manganese-based molecular catalyst comprising an organic ligand. The gas diffusion electrode may provide a selective electrochemical reduction of carbon dioxide to carbon monoxide, in preference to hydrogen, and may be useful for the production of carbon monoxide from industrial waste gas streams of carbon dioxide. A nickel-based molecular catalyst and a method of electrochemical reduction of carbon dioxide are also disclosed.
C25B 11/032 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par la configuration ou la forme perforées ou foraminées Électrodes poreuses Électrodes à diffusion de gaz
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stables; Assemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
C25B 11/095 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques au moins un des composés est de type organique
26.
Method of Parallel Implementation in Distributed Memory Architectures
The present techniques relate to a method for a parallel implementation of a sequential Monte Carlo (SMC) method of modelling an industrial process on a distributed memory architecture, and a system for implementing the same. The method may comprise receiving, from at least one sensor, a measurement of at least one parameter within the physical system, wherein the at least one parameter is related to the true state of the physical system; and implementing, on a server comprising a distributed memory architecture, a sequential Monte Carlo (SMC) process using a plurality of statistically independent particles and the at least one measured parameter to estimate the true state of the physical system, wherein the distributed memory architecture has a plurality of cores each of which are ranked. The method and architecture provide an efficient parallel implementation by effectively parallelising a redistribute step which may be considered to be a constituent part of a resampling step. The SMC method may be used to perform state estimation of dynamic or static models under non-linear, non-Gaussian noise.
G06F 7/08 - Tri, c. à d. rangement des supports d'enregistrement dans un ordre de succession numérique ou autre, selon la classification d'au moins certaines informations portées sur les supports
There is provided an immunogenic composition comprising at least two antigenic determinants, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium; an immunogenic composition comprising a genetic construct or constructs encoding at least two antigenic determinants, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium; and an immunogenic composition comprising at least one antigenic determinant and a genetic construct or constructs encoding at least one different antigenic determinant, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium. There are also provided vaccines, methods of treating or preventing or immunising against Streptococcus pneumoniae bacterium infections and kits comprising immunogenic compositions.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The present invention relates to methods of detecting an infection in a subject based on the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27. In particular, the invention relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infections using the gene pair. Further, the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention, and monitoring the therapeutic effectiveness.
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
29.
Composition of Transparent Conductive Material and Method for Fabricating the same
A film comprising a set of layers including a first layer, a third layer and a second layer therebetween is described. The first layer comprises and/or is a transparent conductive oxide, TCO, having a formula: A1B1O3-δ1; The third layer comprises and/or is a transparent wide-bandgap semiconductor oxide having a formula: A3B303-δ3; The second layer comprises and/or is an oxide layer having a formula: A1αA31-αB1O3-δ2 or A1αA31-αB3O3-δ2 or A3B1βB31-βO3-δ2 or A1αA31-αB1βB31-βO3-δ2; wherein 0<α, β<1, −0.5≤δ1, δ2, δ3≤0.5.
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
A method of reconstructing an electron microscopy image of size [M x N] pixels of a first sample, the method implemented by a computer comprising a processor and a memory, the method comprising: providing a set of pre-learned dictionaries, including a first pre-learned dictionary including a set of p1 atoms; acquiring a sparse set of S acquired sub-images, including a first sub-image of size [a x b] pixels wherein a, b ϵ [2,min{M, N}], of the first sample; and reconstructing the electron microscopy image of the first sample using the sparse set of S sub- images of the first sample and the set of pre-learned dictionaries.
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
According to the subject-matter of the present disclosure, there is provided a computer- implemented method of determining if a medical data sample requires referral for investigation for a disease. The method comprises: performing a pairwise comparison of the medical data sample against each example of medical data in a reference data set using one or more machine learning algorithms to determine a difference in severity of the medical data compared to each example medical data in the reference data set; and flagging the medical data sample as requiring referral for investigation for the disease based on results of the pairwise comparisons, wherein the reference data set includes a plurality of medical data examples, the plurality of medical data examples ranked according to their degree of severity of disease
The present disclosure relates to a computer-implemented method of determining if a fundus image requires referral for investigation for a disease. The method comprises: performing a pairwise comparison of the fundus image against each example fundus image in a reference image set using one or more machine learning algorithms to determine a difference in severity of the fundus image compared to each example fundus image in the reference image set; and flagging the fundus image as requiring referral for investigation for the disease based on results of the pairwise comparisons, wherein the reference image set includes a plurality of example fundus images, the plurality of example fundus images ranked according to their degree of severity of disease.
abyz1.250.6251.12533F. The solid crystalline material may have improved long-term cycling performance, capacity and rate performance compared to known cathode materials. A cathode for a lithium-ion battery comprising the solid crystalline material, a lithium- ion battery comprising the cathode and a method of preparing the solid crystalline material are also disclosed.
Methods of treating viral diseases are disclosed herein. Certain methods include diagnostic methods that quantify levels of biological features associated with TFH or CD4-CTL cells. Certain methods include treatment methods that affect the number, functionality, activity, or expression of TFH or CD4-CTL cells or TREG cells.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour le typage de tissu ou de cellule, p.ex. sondes d’antigène leucocytaire humain [HLA]
The present invention relates to solid compositions of pharmaceutically active compounds, aqueous dispersions derived from these compositions and processes for the preparation of these solid compositions and dispersions. The present invention also relates to pharmaceutical compositions derived from these solid compositions and dispersions, and their use in the treatment and/or prophylaxis of helminthic, protozoal, and viral infections.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A61K 31/4409 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 4, p.ex. isoniazide, iproniazide
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
There is provided an air decontamination system (100). The air decontamination system (100) comprises a conduit for air (110), a pulse generator (130) and a plurality of plasma generation devices (120). The pulse generator (130) is couplable to a power supply and configured to generate a first pulse having a first pulse width of a first predetermined time, thereby controlling airflow between the plurality of plasma generation devices (120) in the conduit (110). The plurality of plasma generation devices (120) is located on two interior surfaces (111, 112) of the conduit (110). Each plasma generation device (120) comprises a high voltage electrode (121) and a ground electrode (122), the electrodes (121, 122) coupled to the pulse generator (130), and a dielectric barrier (123) between the high voltage electrode (121) and the ground electrode (122). The electrodes (121, 122) are configured to apply a voltage across the dielectric barrier (123) to generate a plasma on a surface of the dielectric barrier (123), thereby decontaminating surrounding air.
The present invention relates to novel pharmaceutical formulations. More specifically, the present invention relates to novel pharmaceutical formulations that are suitable for administration to the eye. The present invention also relates to the use of these formulations for the treatment of collagenic eye disorder such as, for example, the treatment of keratoconus.
A61K 47/18 - Amines; Amides; Urées; Composés d’ammonium quaternaire; Acides aminés; Oligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A recyclable thermosetting composition comprises a polymer which is a branched vinyl polymer prepared by transfer-dominated branching radical telomerisation (TBRT) of multivinyl monomer(s) and optionally monovinyl monomer(s) in the presence of chain transfer agent(s), and wherein said polymer comprises curable functional group(s), wherein said curable functional group(s) is/are selected from: an epoxy group; an acid group or other reactive carboxyl or acyl functionality; a hydroxy group or activated hydroxy group; an isocyanate group or blocked isocyanate group; or an amine group. Recycling may comprise recuring using heat, and optionally physically breaking down the recyclable thermoset resin prior to said recuring using heat.
A powder coating composition comprises a polymer which is a branched vinyl polymer prepared by transfer-dominated branching radical telomerisation (TBRT) of multivinyl monomer(s) and optionally monovinyl monomer(s) in the presence of chain transfer agent(s), and wherein said polymer comprises curable functional group(s). Said curable functional group may for example comprise an epoxy group.
The present invention relates to nanoparticles comprising an inverse vulcanised sulfur polymer and a method of forming said nanoparticles. The invention also relates to a water filtration membrane comprising the nanoparticles as well as sorbents comprising the nanoparticles. The invention also relates to the use of such nanoparticles in heavy metal remediation or extraction. The invention also relates to methods of removing heavy metals from fluids.
B01D 53/02 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse
B29C 48/40 - Moyens pour plastifier ou homogénéiser la matière à mouler ou pour la forcer dans la filière ou la matrice utilisant des vis entourées par un fourreau coopérant, p.ex. des extrudeuses à vis simple utilisant au moins deux vis parallèles, p.ex. extrudeuses à vis doubles
C07C 319/04 - Préparation de thiols, de sulfures, d'hydropolysulfures ou de polysulfures de thiols par addition de sulfure d'hydrogène ou de ses sels à des composés non saturés
43.
Surface modified unit cell lattice structures for optimized secure freeform fabrication
Aspects of the present disclosure relate generally to preparing models of three-dimensional structures. In particular, a model of a three-dimensional structure constructed of porous geometries is prepared. A component file including a porous CAD volume having a boundary is prepared. A space including the porous CAD volume is populated with unit cells. The unit cells are populated with porous geometries having a plurality of struts having nodes on each end. The space is populated with at least one elongated fixation element extending beyond the boundary to produce an interlocking feature enabling assembly or engagement with a mating structure.
Liverpool School of Tropical Medicine (Royaume‑Uni)
The University of Liverpool (Royaume‑Uni)
Eisai R&D Management Co., Ltd. (Japon)
Inventeur(s)
Ward, Stephen A.
Taylor, Mark J.
O’neil, Paul M.
Hong, Weiqian David
Benayoud, Farid
Abrégé
The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof.
The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof.
The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof.
The present invention also relates to pharmaceutical compositions comprising compounds of Formulae I and II, and to the use of compounds of Formulae I and II in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.
A method of preparing the herbicidal carboxylic acid aqueous suspension comprising providing a liquid composition of the carboxylic acid herbicide in the form of a solution comprising a solvent for the carboxylic acid herbicide; combining the liquid composition with an aqueous phase precipitant, optionally comprising one or more of a water-soluble polymer and surfactant, under conditions of high shear mixing to cause the solution to precipitate the carboxylic acid herbicide from the solution into the aqueous phase, wherein the aqueous phase is of temperature less than the melting point of the carboxylic acid herbicide; and forming a suspension of the carboxylic acid herbicide precipitate in the aqueous phase.
A01N 25/30 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles caractérisés par les agents tensio-actifs
A01N 39/02 - Acides aryloxycarboxyliques; Leurs dérivés
The present invention relates to hydrogels, methods of making them, their use in the treatment of eye disorders and as bandage contact lenses. The present invention also provides modified poly-ε-lysine polymers and methods of making them.
CLATTERBRIDGE CANCER CENTRE, NHS FOUNDATION TRUST (Royaume‑Uni)
Inventeur(s)
Coyle, Seamus
Probert, Chris
Abrégé
The present invention relates to prognostic urinary or blood biomarkers that can be used to help predict the how long an individual in the later stages of life might have before their death occurs. Thus, the present invention therefore provides a method of determining the probability that an individual will die within a specified period time, typically up to three months, by testing a urine or blood sample obtained from the individual concerned for the presence of certain prognostic biomarkers and analysing the variance data with a predictive model.
a41-x1-bbb, wherein b is from 0 to 0.5; and X and Z are each independently selected from O, S, F, Cl, Br, I or a mixture thereof. The solid crystalline material suitably provides a solid ionic conductor for use in a solid-state battery. A solid crystalline material comprising a solid solution, a solid-state battery comprising the solid crystalline material and a method of preparing the solid crystalline are also disclosed.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
A solid crystalline material of formula (I): AzDY4Xx, wherein each A is independently selected from Li, Na, K and Mg; D is selected from Si, Al, P, B, Ga, Ge, S, Mo, W, V, Sn, Sb, Nb and Ta, or a mixture thereof; each Y is independently selected from O, S, F, Cl, Br or a mixture thereof; each X is independently selected from F, Cl, Br, I, O, S, BH4 or a mixture thereof; z is from 2 to 8; and x is from 1 to 3. The solid crystalline material suitably provides a solid ionic conductor for use in a solid-state battery. A mixed solid crystalline material comprising the solid crystalline material, a solid-state battery comprising the solid crystalline material and a method of preparing the solid crystalline are also disclosed.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
A High Voltage Complementary Metal-Oxide-Semiconductor, HV-CMOS, sensor comprising a p-substrate having a topside and a backside; wherein the topside comprises: an array of mutually spaced apart pixel structures, including a first pixel structure, therein and/or thereon, wherein the first pixel structure comprises: a set of PMOS and NMOS transistors, including a first PMOS transistor having an n-well, SN, layer, and a first NMOS transistor having a p-well, SP, layer; a deep n-well, DN, structure having a DN layer; a p-type buried, BP, layer disposed to mutually isolate the SN layer and the DN layer; an n-type buried, BN, layer providing a SN/BN/DN stack; and a set of contacts, including a first contact, electrically coupled to the DN layer via the SN/BN/DN stack; wherein the backside comprises: a doped p+ layer therein and/or thereon; and wherein the sensor comprises an HV bias contact electrically coupled only to the p+ layer, for backside biasing thereof.
A transmitter for inductive charging of a device comprising a receiver is provided. The transmitter includes a set of coils, including a first coil having a first turn and a second turn. The first turn and the second turn are adjacent. The first turn has the first sense and the second turn has the second sense, opposed to the first sense; whereby, in use, current flows through the first turn and the second turn in opposed senses.
An apparatus for forming a C1 to C5 oxygenate from carbon dioxide and a C1 to C4 hydrocarbon is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the C1 to C4 hydrocarbon and an outlet for the oxygenates. In one example the passageway includes therein a catalyst. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide in reacted with the C1 to C4 hydrocarbon in the generated plasma, thereby forming the oxygenates from at least some of the carbon dioxide and the C1 to C4 hydrocarbon. The DBD device comprises a conducting liquid as a ground electrode. A method and a use are also described.
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage
C07C 29/48 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par des réactions d'oxydation avec formation de groupes hydroxyle
C07C 51/215 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par oxydation avec l'oxygène moléculaire de groupes hydrocarbyle saturés
53.
CO2 HYDROGENATION TO OXYGENATES USING PLASMA CATALYSIS
An apparatus for forming C1 to C5 alcohol, carboxylic acid, or mixture thereof from carbon dioxide and hydrogen is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the hydrogen and an outlet for the C1 to C5 alcohol, carboxylic acid, or mixture thereof and including therein a catalyst comprising nickel and/or cobalt and/or copper on a support. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide is exposed to the catalyst in the presence of the hydrogen in the generated plasma, thereby forming the C1 to C5 alcohol, carboxylic acid, or mixture thereof from at least some of the carbon dioxide and the hydrogen. The DBD devices comprises a water electrode. A method and a catalyst are also described.
B01J 37/34 - Irradiation ou application d'énergie électrique, magnétique ou ondulatoire, p.ex. d'ondes ultrasonores
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
C07C 27/06 - Procédés impliquant la production simultanée de plusieurs classes de composés contenant de l'oxygène par réduction de composés oxygénés par hydrogénation d'oxydes de carbone
C07C 29/154 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction exclusivement des oxydes de carbone avec de l'hydrogène ou des gaz contenant de l'hydrogène caractérisée par le catalyseur utilisé contenant du cuivre, de l'argent, de l'or ou leurs composés
An apparatus for forming methane from carbon dioxide and hydrogen is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the hydrogen and an outlet for the methane and including therein a catalyst comprising nickel and alumina. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide is exposed to the catalyst in the presence of the hydrogen in the generated plasma, thereby forming the methane from at least some of the carbon dioxide and the hydrogen. A method, a use and a catalyst are also described.
C07C 1/12 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone à partir d'anhydride carbonique avec de l'hydrogène
A solid composition comprising nanoparticles of atovaquone dispersed within one or more carrier materials, wherein the atovaquone is present in an amount of at least 10 wt %. Also described is an intramuscularly- or subcutaneously-injectable formulation of nanoparticles of atovaquone.
The present invention relates to novel sulfur-doped carbonaceous porous materials. The present invention also relates to processes for the preparation of these materials and to the use of these materials in applications such as gas adsorption, mercury and gold capture, gas storage and as catalysts or catalyst supports.
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01D 53/02 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
C01B 32/318 - Préparation caractérisée par les matières de départ
C01B 32/342 - Préparation caractérisée par des agents d’activation non gazeux
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
C25B 11/091 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
The present invention relates to A device for performing an assay on an aqueous biological sample, the device comprising: (i) at least a first chamber comprising a desiccated hydrogel, wherein the hydrogel incorporates at least a first desiccated assay reagent or reagents, the hydrogel and reagent or reagents being configured to allow the controlled release of the first reagent or reagents when the hydrogel has been exposed to the aqueous biological sample and has at least been partially hydrated; and (ii) an imaging device for imaging and analysing the first chamber after the aqueous biological sample has been introduced into the first chamber and the hydrogel has been at least partially hydrated and at least part of the first reagent or reagents has or have been released. The present invention also relates to a device for rapidly determining the susceptibility of a microorganism in an aqueous biological sample to an antimicrobial agent comprising: a) a multi-chamber plate, wherein: (i) at least a first chamber comprises a growth medium, a first dye, and a desiccated hydrogel; and (ii) at least a second chamber comprises a growth medium, a first dye, a desiccated hydrogel, and a first antimicrobial agent that inhibits or slows the proliferation of the, or a, microorganism; and b) an imaging device for imaging and analysing one or more chambers after the biological sample has been introduced into the chamber and the hydrogel has been at least partially hydrated. The invention also relates to related methods and a kit of parts. The device is particularly suited for identifying the which antimicrobial agents would be suitable for the treatment of microbial infections, such as Urinary Tract Infections (UTIs).
The present invention relates to a combination of fluorescent dyes for identifying, or differentiating between, different bacterial strains, wherein the combination comprises two or more of the following fluorescent dyes: SYBR Green I, SYTO 13 or 9, and/or DiSC3(5) and/or FM4-64. The device is particularly suited for identifying the type of bacterial infection causing a Urinary Tract Infection (UTI) and can be used to help identify which antimicrobial agents would be suitable for the treatment the infection.
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
59.
DEFECT IDENTIFICATION IN ADDITIVE MANUFACTURING BASED ON TIME SERIES IN-PROCESS PARAMETER DATA
pdtt X,Ytt pdt,t, estpdt-t- npdt,t, estpdtt t of the in-process parameter; and identifying a defect in the article based, at least in part, on a result of the comparing.
B22F 10/28 - Fusion sur lit de poudre, p.ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p.ex. le lissage de la surface, la densité, la porosité ou des structures creuses
B22F 10/85 - Acquisition ou traitement des données pour la commande ou la régulation de procédés de fabrication additive
B22F 12/90 - Moyens de commande ou de régulation des opérations, p.ex. caméras ou capteurs
B33Y 30/00 - Appareils pour la fabrication additive; Leurs parties constitutives ou accessoires à cet effet
B33Y 50/02 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
B29C 64/153 - Procédés de fabrication additive n’utilisant que des matériaux solides utilisant des couches de poudre avec jonction sélective, p.ex. par frittage ou fusion laser sélectif
B29C 64/393 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (Norvège)
Inventeur(s)
Blakey, David
Voutila, Jon
Papadimitropoulos, Thanos
Hamill, Kevin
Willoughby, Colin
Abrégé
The disclosure relates to saRNAs useful in upregulating the expression of a target gene and therapeutic compositions comprising the saRNAs, wherein the target gene is PAX6. Methods of using the saRNAs and the therapeutic compositions are also provided.
A composition is described, having a relative permittivity, preferably a real part ε′γ of a relative complex permittivity εγ, substantially inversely proportional to the square of a frequency of an alternating electrical field, preferably due to an electromagnetic field, for example applied thereto and/or propagating therethrough.
H01B 3/00 - Isolateurs ou corps isolants caractérisés par le matériau isolant; Emploi de matériaux spécifiés pour leurs propriétés isolantes ou diélectriques
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
UNIVERSITY OF LIVERPOOL (Royaume‑Uni)
CENTERS FOR DISEASE CONTROL AND PREVENTION (USA)
Inventeur(s)
Campo, David S.
Urbanowicz, Richard A.
Abouhaidar, Mounir G.
Mosa, Alexander I.
Feld, Jordan J.
Abrégé
There is described herein polyvalent HCV vaccines, preferably comprising SEQ ID Nos. 1-5. There is also described herein methods of designing polyvalent vaccines.
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
UNIVERSITY OF LIVERPOOL (Royaume‑Uni)
CENTERS FOR DISEASE CONTROL AND PREVENTION (USA)
Inventeur(s)
Mosa, Alexander I.
Feld, Jordan J.
Abrégé
There is described herein polyvalent HCV vaccines, preferably comprising SEQ ID Nos. 1-5. There is also described herein methods of designing polyvalent vaccines.
Provided herein are methods for one or more of a) modulating an immune response to a tumor cell in a patient, b) treating cancer in a cancer patient; or c) eliciting an anti-tumor response in a patient, comprising modulating the expression or activity of Junction Adhesion Molecule Like (JAML).
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention relates to solid compositions comprising microparticles of tenofovir alafenamide and/or bictegravir dispersed within a matrix comprising a first excipient and a second excipient. The present invention also relates to microneedle arrays, implantable rods, aqueous dispersions, and pharmaceutical compositions derived from said solid compositions and uses for the same.
An apparatus for forming CO2-free hydrogen and carbon nanomaterials from methane is described. The apparatus comprises: a gliding arc discharge, GAD, device arranged to generate a plasma; and a passageway including an inlet for the methane and an outlet for the hydrogen and carbon and/or carbon nanomaterials, wherein the passageway extends, at least in part, through the GAD device wherein, in use, the methane is reacted in the generated plasma at temperatures of at most 400 °C and atmospheric pressure, thereby forming the hydrogen from at least some of the methane. A method is also described.
C01B 3/24 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés organiques gazeux ou liquides d'hydrocarbures
68.
METHOD AND APPARATUS RELATED TO SIMULATION OF IMAGES
A method of simulating an electron microscopy image of a sample is described. The method implemented by a computer comprising a processor and a memory. The method comprises: obtaining parameters of the electron microscopy, attributes of the sample and respective thresholds of one or more target properties of the simulated electron microscopy image; and computing the simulated electron microscopy image of size [M x N] pixels of the sample using the obtained parameters of the electron microscope and the obtained attributes of the sample, according to the obtained respective thresholds of the one or more target properties of the simulated electron microscopy image.
The present invention relates to solid compositions comprising microparticles of glecaprevir and/or pibrentasvir dispersed within a matrix comprising a first excipient and a second excipient. The present invention also relates to microneedle arrays, implantable rods, aqueous dispersions, and pharmaceutical compositions derived from said solid compositions and uses for the same.
There is provided an imaging device (100) for imaging a target, the imaging device (100) comprising a Scheimpflug imaging system (102) and an Optical Coherence Tomography, OCT, imaging system (104), where the Scheimpflug imaging system (102) comprises a camera (112) and a lens system (108), and the OCT imaging system (104) comprises an imaging optical element and a detector (122). The imaging device (100) further comprises a light source (106) adapted to provide a light beam suitable for operation of the Scheimpflug imaging system (102) and the OCT imaging system (104). The lens system (108) of the Scheimpflug imaging (102) system is configured to provide an adjustable focal length.
A61B 3/18 - Agencement de plusieurs appareils pour tester ou examiner les yeux
A61B 3/00 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
71.
SYSTEM AND METHOD FOR OBTAINING BIOMECHANICAL PARAMETERS OF OCULAR TISSUE THROUGH DEFORMATION OF THE OCULAR TISSUE
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Espagne)
INSTYTUT CHEMII FIZYCZNEJ (Pologne)
THE UNIVERSITY OF LIVERPOOL (Royaume‑Uni)
Inventeur(s)
Curatolo, Andrea
Marcos Celestino, Susana
Birkenfeld, Judith
Wojtkowski, Maciej
Karnowski, Karol
Elsheikh, Ahmed
Abass, Ahmed
Eliasy, Ashkan
Abrégé
A system for obtaining biomechanical parameters of ocular tissue includes
an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and
an imaging device operatively coupled to the air-puff module.
A system for obtaining biomechanical parameters of ocular tissue includes
an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and
an imaging device operatively coupled to the air-puff module.
The air-puff module includes a transparent window at its front with a transparent through hole for delivering the air-puff stimulus. The hole is aligned with an imaging device optical axis, such that the air-puff stimulus delivered onto the ocular tissue can be centred on an apex of the ocular tissue and made collinear with the optical axis. The transparent window and through hole allow continuity of imaging of the ocular surface.
A system for obtaining biomechanical parameters of ocular tissue includes
an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and
an imaging device operatively coupled to the air-puff module.
The air-puff module includes a transparent window at its front with a transparent through hole for delivering the air-puff stimulus. The hole is aligned with an imaging device optical axis, such that the air-puff stimulus delivered onto the ocular tissue can be centred on an apex of the ocular tissue and made collinear with the optical axis. The transparent window and through hole allow continuity of imaging of the ocular surface.
The imaging device captures the 3D coordinates of points distributed on an ocular tissue surface in groups of simultaneous points.
A system for obtaining biomechanical parameters of ocular tissue includes
an air-puff module to deliver an air-puff stimulus onto the ocular tissue, and
an imaging device operatively coupled to the air-puff module.
The air-puff module includes a transparent window at its front with a transparent through hole for delivering the air-puff stimulus. The hole is aligned with an imaging device optical axis, such that the air-puff stimulus delivered onto the ocular tissue can be centred on an apex of the ocular tissue and made collinear with the optical axis. The transparent window and through hole allow continuity of imaging of the ocular surface.
The imaging device captures the 3D coordinates of points distributed on an ocular tissue surface in groups of simultaneous points.
The system includes a component for selecting and changing location and distribution of captured points on the ocular tissue, and a
processing component to process the points.
A61B 3/16 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la pression intraoculaire, p.ex. tonomètres
A61B 3/18 - Agencement de plusieurs appareils pour tester ou examiner les yeux
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A three-dimensional metal-organic framework, MOF, comprising a plurality of crystallographically-ordered heterolinkers, including a first linker and a second linker, respectively periodically arranged between metal nodes, defining cages having a plurality of mutually different window types, including a first window type and a second window type, therebetween, wherein the respective window types correspondingly comprise mutually different heterolinker arrangements.
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
C07F 7/00 - Composés contenant des éléments des groupes 4 ou 14 de la classification périodique
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
73.
Reduced spatial/temporal overlaps to increase temporal overlaps to increase precision in focused ion beam FIB instruments for milling and imaging and focused ion beams for lithography
A beam control method is provided that can be implemented with any hardware system for imaging and/or cutting such as SEM/FIB/HIM or charged particle lithography which alleviates the deposited energy overlap between pixels to increase resolution and precision while reducing damage. The method includes scanning a workpiece with e-beam lithography, proton lithography, ion beam lithography, optical lithography, ion beam imaging or FIB in a reduced or sub-sampled pattern, to reduce beam overlap, which can include the step of scanning the beam ensuring that there is the largest difference in time and space between consecutive beam locations.
H01J 37/147 - Dispositions pour diriger ou dévier la décharge le long d'une trajectoire déterminée
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
H01J 37/305 - Tubes à faisceau électronique ou ionique destinés aux traitements localisés d'objets pour couler, fondre, évaporer ou décaper
H01J 37/317 - Tubes à faisceau électronique ou ionique destinés aux traitements localisés d'objets pour modifier les propriétés des objets ou pour leur appliquer des revêtements en couche mince, p.ex. implantation d'ions
74.
METHOD AND APPARATUS USING ABSORPTION SPECTROSCOPY FOR DISCRIMINATION OF TISSUE OR CELLS
A method of discriminating between first cell types or first tissue types and second cell types or second tissue types is described. At S601, the method comprises providing a cell sample or a tissue sample including a first spatial region, comprising a first cell type or a first tissue type, and a second spatial region. At S602, the method comprises obtaining a first absorption response comprising: illuminating the first spatial region using emitted infrared, IR, electromagnetic radiation, EMR, incident thereupon, wherein the IR EMR comprises a set of pairs of discrete wavelengths, including a first pair of discrete wavelengths consisting of a first wavelength and a second wavelength, wherein the first pair of discrete wavelengths is characteristic of a discriminating biomarker; and detecting respective absorbances of the incident first wavelength and the incident second wavelength of the first pair of discrete wavelengths by the first spatial region. At S603, the method comprises obtaining a second absorption response comprising: illuminating the second spatial region using the IR EMR; and detecting respective absorbances of the incident first wavelength and the incident second wavelength of the first pair of discrete wavelengths by the second spatial region. At S604, the method comprises discriminating between the first spatial region and the second spatial region based on a result of comparing the obtained first absorption response and the obtained second absorption response.
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
G01N 21/3563 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de solides; Préparation des échantillons à cet effet
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
75.
BONE MARROW MESENCHYMAL STEM CELL DERIVED CELL POPULATIONS AND METHODS OF PREPARING SAME
Provided are populations of cells enriched for MSC-derived cells that are: CD90+; CD105+; CD45−; as well as TIMP-1 secretion high, and MMP13 gene expression low. Such populations of cells are useful as medicaments in contexts where it is desired to make use of the trophic or immunosuppressive therapeutic effects of MSCs, but to avoid activity associated with the capacity of MSCs to undergo phenotypic differentiation. Populations of cells of the invention are useful in the treatment of a condition selected from the group consisting of: osteoarthritis; myocardial infarction; meniscus cartilage injury (such as torn meniscus); ligament injury (such as torn ligament); injuries to the skin; and soft tissue injury. They may also be used in treatment of a disease selected from the group consisting of: haematological disease; graft-versus-host disease; and inflammatory disease.
The present invention relates to a method of determining the probability that an individual has irritable bowel syndrome and whether the individual will respond to dietary intervention. The present invention also provides a method of determining the probability that an individual with irritable bowel syndrome will respond to dietary intervention. There is also provided the use of a compound as defined herein as a biomarker.
G01N 33/64 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des cétones
The present invention relates to methods of preferentially sorbing, from a target mixture, one or more target substance(s) over one or more non-target substance(s). In particular, porous organic cages (POCs) may be deployed in the quantum sieving of mixtures of hydrogen isotopes to selectively sorb heavy hydrogen isotopes (e.g. diatomic deuterium) over lighter isotopes (diatomic protium).
A method of characterizing a liquid exposed to ionizing radiation, the method comprising: including an oxidizing agent and/or a reducing agent of a redox pair in the liquid, thereby providing a corresponding redox couple; determining a first redox potential due, at least in part, to the redox couple while exposing the liquid to the ionizing radiation.
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
G01N 27/48 - Systèmes utilisant la polarographie, c. à d. la mesure des variations d'intensité sous une tension qui varie lentement
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
79.
METHOD OF PARALLEL IMPLEMENTATION IN DISTRIBUTED MEMORY ARCHITECTURES
The present techniques relate to a method for a parallel implementation of a sequential Monte Carlo (SMC) method of modelling an industrial process on a distributed memory architecture, and a system for implementing the same. The method may comprise receiving, from at least one sensor, a measurement of at least one parameter within the physical system, wherein the at least one parameter is related to the true state of the physical system; and implementing, on a server comprising a distributed memory architecture, a sequential Monte Carlo (SMC) process using a plurality of statistically independent particles and the at least one measured parameter to estimate the true state of the physical system, wherein the distributed memory architecture has a plurality of cores each of which are ranked. The method and architecture provide an efficient parallel implementation by effectively parallelising a redistribute step which may be considered to be a constituent part of a resampling step. The SMC method may be used to perform state estimation of dynamic or static models under non-linear, non-Gaussian noise.
There is provided an immunogenic composition comprising at least two antigenic determinants, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium; an immunogenic composition comprising a genetic construct or constructs encoding at least two antigenic determinants, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium; and an immunogenic composition comprising at least one antigenic determinant and a genetic construct or constructs encoding at least one different antigenic determinant, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium. There are also provided vaccines, methods of treating or preventing or immunising against Streptococcus pneumoniae bacterium infections and kits comprising immunogenic compositions.
There is provided an immunogenic composition comprising at least two antigenic determinants, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium; an immunogenic composition comprising a genetic construct or constructs encoding at least two antigenic determinants, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium; and an immunogenic composition comprising at least one antigenic determinant and a genetic construct or constructs encoding at least one different antigenic determinant, wherein the antigenic determinants are derived from at least two proteins selected from ABC-T, PavA and ZmpB of a Streptococcus pneumoniae bacterium. There are also provided vaccines, methods of treating or preventing or immunising against Streptococcus pneumoniae bacterium infections and kits comprising immunogenic compositions.
An electrochemical cell comprising a gas diffusion electrode for the electrochemical reduction of carbon dioxide. The gas diffusion electrode comprises a gas diffusion layer and a nickel or manganese-based molecular catalyst comprising an organic ligand. The gas diffusion electrode may provide a selective electrochemical reduction of carbon dioxide to carbon monoxide, in preference to hydrogen, and may be useful for the production of carbon monoxide from industrial waste gas streams of carbon dioxide. A nickel-based molecular catalyst and a method of electrochemical reduction of carbon dioxide are also disclosed.
C25B 9/19 - Cellules comprenant des électrodes fixes de dimensions stables; Assemblages de leurs éléments de structure avec des diaphragmes
C25B 11/032 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par la configuration ou la forme perforées ou foraminées Électrodes poreuses Électrodes à diffusion de gaz
C25B 11/054 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support Électrodes comportant des électro-catalyseurs sur un support
C25B 11/057 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau du substrat ou du support formé d’un seul élément ou composé
A method of manufacturing, at least in part, a gas electron multiplier, GEM, is described. At S101, the method comprises providing a precursor, comprising a substrate, for example a sheet or a plate, having opposed first and second surfaces. At S102, the method comprises masking the first surface of the precursor using a first mask defining a first set of apertures, including a first aperture, at least partly therethrough. At S103, the method comprises perforating the masked precursor, thereby forming a set of perforations, including a first perforation, at least partly therethrough, wherein the set of perforations corresponds, at least in part, to the first set of apertures; wherein perforating the masked precursor comprises, at least in part, abrading the masked precursor, for example by abrasive etching, via the first set of apertures. A GEM is also described.
A film comprising a set of layers including a first layer, a third layer and a second layer therebetween is described. The first layer comprises and/or is a transparent conductive oxide, TCO, having a formula: A1B13 — δ13 — δ1; The third layer comprises and/or is a transparent wide-bandgap semiconductor oxide having a formula: A3B33- δ33- δ3; The second layer comprises and/or is an oxide layer having a formula: A1ααA31-α1-αB13-δ23-δ2 or A1ααA31-α1-αB33-δ2 A3B1ββB31-β3-δ23-δ2 or A1ααA31-α1-αB1ββB31-β3-δ2 1233 ≤ 0.5.
H01B 1/08 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisés; Emploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques oxydes
H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives
H01L 51/44 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement - Détails des dispositifs
The present invention relates to solid compositions of pharmaceutically active compounds, aqueous dispersions derived from these compositions and processes for the preparation of these solid compositions and dispersions. The present invention also relates to pharmaceutical compositions derived from these solid compositions and dispersions, and their use in the treatment and/or prophylaxis of helminthic, protozoal, and viral infections.
INSERM (Institut National de la Santé et de la Recherche Médicale) (France)
Université de Bordeaux (France)
Centre National de la Recherche Scientifique (CNRS) (France)
Université Cote d'Azur (France)
University of Liverpool (Royaume‑Uni)
Inventeur(s)
Bikfalvi, Andreas
Cooley, Lindsay
Souleyreau, Wilfried
Pages, Gilles
Falciani, Francesco
Dufies, Maeva
Clarke, Kim
Abrégé
Renal Cell Carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and has a worldwide mortality. However, mortality rates have barely improved over the last 20 years. Novel biomarkers and biomarkers are thus urgently required for this cancer. The inventors have devised a strategy to produce mouse cancer cell lines of progressively enhanced aggressiveness and specialization. The mouse renal cancer cell line RENCA was serially passaged in vivo using multiple implantation strategies designed to replicate different aspects of primary tumour growth and metastasis. Transcriptomic and epigenomic data has been acquired for the derived cell lines and primary analyses have been performed. The inventors then selected plurality of genes with no reported role in RCC which were upregulated in their specialized cell lines, and checked their relevance in patient data and clinical samples. This approach contributes to identify 4 serum biomarkers, namely IL-34, SAA2, PONL1 and CFB that are suitable for predicting survival time in patients suffering from RCC. The inventors also validated that the 4 proteins are also biotargets for the treatment of RCC.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
88.
METHOD AND APPARATUS FOR PROVIDING A FIBER-REINFORCED COMPOSITE MATERIAL
A method of providing a fibre-reinforced composite material, the method comprising: dispersing particles of a first polymeric composition comprising a first thermoplastic in a liquid comprising water, thereby forming a dispersion; coating, at least in part, a first set of reinforcement fibres with the dispersion; redistributing the particles of the first polymeric composition comprised in the coating; and melting at least some of the redistributed particles of the first polymeric composition comprised in the coating, thereby providing the composite material.
The present invention relates to methods of preferentially sorbing, from a target mixture, one or more target substance(s) over one or more non-target substance(s). In particular, porous organic cages (POCs) may be deployed in the quantum seiving of mixtures of hydrogen isotopes to selectively sorb heavy hydrogen isotopes (e.g. diatomic deuterium) over lighter isotopes (diatomic protium).
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
The present invention relates to new synthetically generated carboxysome shells, shells encapsulating selected catalytically active enzymes, cells including the shells and methods of making the shells and methods of encapsulation. The invention also includes uses of the cells as nanoreactors for enhanced catalytic performance of the encapsulated enzymes and the use of an encapsulation protein for recruiting external cargo proteins into a synthetic carboxysome shell.
The present disclosure relates to a diagnostic test for the early detection of pancreatic cancer [i.e. pancreatic ductal adenocarcinoma, ‘PDAC’] or pancreatitis in a cohort of patients selected for an increased risk of PDAC which is associated with diabetes mellitus (DM) and including treatment regimens for the treatment of subjects with PDAC and kits used in the method of the invention.
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/577 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des anticorps monoclonaux
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
Polymer-of-prodrug (POP) materials enable new nucleoside reverse transcriptase inhibitor (NRTI) therapy strategies. The materials are prodrugs of NRTIs in the form of polymers. Suitable materials include products which are polymeric NRTI delivery systems comprising polymeric materials which are capable of degradation after administration to release NRTIs or NRTI prodrugs which themselves are capable of metabolism to the parent NRTIs. The NRTIs may optionally be selected from tenofovir (TFV), emtricitabine (FTC), lamivudine (3TC) and MK-8591 (EFdA). The invention facilitates long-acting (LA) regimens. Constructs of the materials may be in the form of injectable compositions or implants.
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c. à d. le conjugué entier étant un co-médicament, p.ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A composition comprising amorphous silica having a Group I metal content of 500 to 2500ppm and having 2 to 7.6 silanol groups per nm2 is described. Uses and methods are also described.
Responsive or degradable branched polymers may be prepared by the free radical polymerisation of a multivinyl monomer in the presence of a chain transfer agent, using a source of radicals, wherein the extent of propagation is controlled relative to the extent of chain transfer to prevent gelation of the polymer. The multivinyl monomer may comprise a cleavable group, for example an ester, or a multiplicity of such groups, between two vinyl groups. Said monomer may be a macromonomer containing multiple cleavage sites.
C08K 5/375 - Sulfures contenant des cycles aromatiques à six chaînons
C08L 47/00 - Compositions contenant des homopolymères ou des copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, l'un au moins contenant plusieurs liaisons doubles carbone-carbone; Compositions contenant des dérivés de tels polymères
The invention relates to a method for rapidly determining the susceptibility of a microorganism to an antimicrobial agent comprising the steps: a) contacting a first sample containing the microorganism with a first growth medium so as to form a first mixture, wherein the first growth medium is selected to enable the microorganism to proliferate and/or encourage the microorganism cell cycle to commence proliferation; b) contacting a second sample containing the microorganism with a second growth medium so as to form a second mixture, wherein the second growth medium is substantially the same as the first growth medium but further comprises a first antimicrobial agent which may inhibit or slow the proliferation of the microorganism; c) incubating the first and second mixtures, for 30 minutes or less, under conditions suitable to enable or encourage proliferation of the microorganism; d) passing the first and second mixture, or portion thereof, through a flow cytometer in order to assess one or more biochemical and/or biophysical parameters of the microorganisms in both mixtures; and e) comparing the parameters of the microorganisms in the first mixture with that of the second mixture, after incubation, in order to detect whether the first antimicrobial agent inhibits or slows the proliferation of the microorganism so as to determine the susceptibility of a microorganism to said agent. The method is particularly suited for identifying the which antimicrobial agents would be suitable for the treatment of microbial infections, such as Urinary Tract Infections (UTIs)
An apparatus for forming methane from carbon dioxide and hydrogen is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the hydrogen and an outlet for the methane and including therein a catalyst comprising nickel and alumina. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide is exposed to the catalyst in the presence of the hydrogen in the generated plasma, thereby forming the methane from at least some of the carbon dioxide and the hydrogen. A method, a use and a catalyst are also described.
B01J 19/02 - Appareils caractérisés par le fait qu'ils sont construits avec des matériaux choisis pour leurs propriétés de résistance aux agents chimiques
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
B01J 23/78 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du cuivre ou des métaux du groupe du fer en combinaison avec des métaux, oxydes ou hydroxydes prévus dans les groupes avec des métaux alcalins ou alcalino-terreux ou du béryllium
B01J 23/83 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du cuivre ou des métaux du groupe du fer en combinaison avec des métaux, oxydes ou hydroxydes prévus dans les groupes avec des terres rares ou des actinides
97.
2 HYDROGENATION TO OXYGENATES USING PLASMA CATALYSIS
An apparatus for forming C1 to C5 alcohol, carboxylic acid, or mixture thereof from carbon dioxide and hydrogen is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the hydrogen and an outlet for the C1 to C5 alcohol, carboxylic acid, or mixture thereof and including therein a catalyst comprising nickel and/or cobalt and/or copper on a support. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide is exposed to the catalyst in the presence of the hydrogen in the generated plasma, thereby forming the C1 to C5 alcohol, carboxylic acid, or mixture thereof from at least some of the carbon dioxide and the hydrogen. The DBD devices comprises a water electrode. A method and a catalyst are also described.
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage
C07C 29/152 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction exclusivement des oxydes de carbone avec de l'hydrogène ou des gaz contenant de l'hydrogène caractérisée par le réacteur utilisé
C07C 29/156 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction exclusivement des oxydes de carbone avec de l'hydrogène ou des gaz contenant de l'hydrogène caractérisée par le catalyseur utilisé contenant des métaux du groupe du fer, des métaux du groupe du platine, ou leurs composés
98.
PLASMA CONVERSION REACTOR OF C02 WITH C1 TO C4 HYDROCARBON TO C1 TO C5 OXYGENATE AND METHOD THEREOF
An apparatus for forming a C1 to C5 oxygenate from carbon dioxide and a C1 to C4 hydrocarbon is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the C1 to C4 hydrocarbon and an outlet for the oxygenates. In one example the passageway includes therein a catalyst. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide in reacted with the C1 to C4 hydrocarbon in the generated plasma, thereby forming the oxygenates from at least some of the carbon dioxide and the C1 to C4 hydrocarbon. The DBD device comprises a conducting liquid as a ground electrode. A method and a use are also described.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A solid crystalline material of formula (I): AzDY4Xx, wherein each A is independently selected from Li, Na, K and Mg; D is selected from Si, Al, P, B, Ga, Ge, S, Mo, W, V, Sn, Sb, Nb and Ta, or a mixture thereof; each Y is independently selected from O, S, F, Cl, Br or a mixture thereof; each X is independently selected from F, Cl, Br, I, O, S, BH4 or a mixture thereof; z is from 2 to 8; and x is from 1 to 3. The solid crystalline material suitably provides a solid ionic conductor for use in a solid-state battery. A mixed solid crystalline material comprising the solid crystalline material, a solid-state battery comprising the solid crystalline material and a method of preparing the solid crystalline are also disclosed.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium